INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

Week 24 Advanced MRI analyses detected early treatment-related changes in white matter myelin integrity and cortical microstructure, consistent with biologic activity from selective soluble TNF inhibition. The data suggest the therapy is affecting target biology by 24 weeks, supporting continued clinical development, though no financial metrics or guidance are provided.

Analysis

Week 24 Advanced MRI analyses detected early treatment-related changes in white matter myelin integrity and cortical microstructure, consistent with biologic activity from selective soluble TNF inhibition. The data suggest the therapy is affecting target biology by 24 weeks, supporting continued clinical development, though no financial metrics or guidance are provided.